Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study

Respiratory Research

Volumn 16, Issue 1, 2015, Pages

  Silkoff, P E ^a   Strambu, I ^b   Laviolette, M ^c   Singh, D ^d   FitzGerald, J M ^e,f   Lam, S ^e,f   Kelsen, S ^g   Eich, A ^h   Ludwig Sengpiel, A ⁱ   hupp, G C ^j   Backer, V ^k   Porsbjerg, C ^k   Girodet, P O ^l   Berger, P ^l   Leigh, R ^m   Kline, J N ⁿ   Dransfield, M ^o   Calhoun, W ^p   Hussaini, A ^q   Khatri, S ^r   Chanez, P ^s   Susulic, V S ^a   Barnathan, E S ^a   Curran, M ^a   Das, A M ^a   Brodmerkel, C ^a   Baribaud, F ^a   Loza, M J ^a   more..

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b ARENSIA Exploratory Medicine   (Romania)

^c LAVAL UNIVERSITY   (Canada)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^e Institute for Heart and Lung Health   (Canada)

^f Gordon and Leslie Diamond Health Care Centre Vancouver Coastal Health   (Canada)

^g TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h IKF Clinical Research Centre Respiratory Medicine   (Germany)

ⁱ MEDICAL LASER CENTER LÜBECK   (Germany)

^j YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k BISPEBJERG HOSPITAL   (Denmark)

^l UNIVERSITÉ DE BORDEAUX   (France)

^m UNIVERSITY OF CALGARY   (Canada)

ⁿ UNIVERSITY OF IOWA   (United States)

^o University of Alabama at Birmingham   (United States)

^p UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^q PAREXEL INTERNATIONAL   (United States)

^r LERNER RESEARCH INSTITUTE   (United States)

^s AIX MARSEILLE UNIVERSITY   (France)

more..

Author keywords

Asthma; Biomarkers; Personalized; Phenotypes; Profiling; Severity

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; IMMUNOGLOBULIN E; OMALIZUMAB; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT;

ADULT; AGED; AIRWAY OBSTRUCTION; ALLERGY; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE 7; BRONCHOSCOPY; COMORBIDITY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; EOSINOPHIL COUNT; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; FRACTIONAL EXHALED NITRIC OXIDE; HUMAN; LYMPHOCYTE COUNT; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT DISEASE ASSESSMENT; RESPIRATORY TRACT PARAMETERS; SMOKING; ADOLESCENT; BRONCHOCONSTRICTION; CANADA; CASE CONTROL STUDY; CLINICAL TRIAL; DRUG EFFECTS; EUROPE; LONGITUDINAL STUDY; LUNG; LUNG FUNCTION TEST; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE; PREVALENCE; QUESTIONNAIRE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SPUTUM; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOMARKERS; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; CANADA; CASE-CONTROL STUDIES; EUROPE; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUNG; MALE; MIDDLE AGED; PATIENT SELECTION; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PREVALENCE; RESEARCH DESIGN; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPUTUM; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84947275302     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-015-0299-y     Document Type: Article

References (41)

1. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med. 2000;162:2341-51.
2. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154:573-82.
3. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455-66.
4. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189-97.
5. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198-207.
6. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088-98.
7. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8:183-92.
8. Little SA, Chalmers GW, MacLeod KJ, McSharry C, Thomson NC. Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma. Thorax. 2000;55:232-4.
9. Jang AS, Lee JH, Park SW, Lee YM, Uh ST, Kim YH, et al. Factors influencing the responsiveness to inhaled glucocorticoids of patients with moderate-to-severe asthma. Chest. 2005;128:1140-5.
10. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A. 2007;104:15858-63.
11. National Asthma E, Prevention P. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007;120:S94-S138.
12. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902-7.
13. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest. 1999;115:1265-70.
14. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319-38.
15. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179-87.
16. American Thoracic Society. Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 1999;160:2104-2117.
17. Kelly MM, Efthimiadis A, Hargreave FE. Induced sputum: selection method. Methods Mol Med. 2001;56:77-91.
18. Sideleva O, Dixon AE. The many faces of asthma in obesity. J Cell Biochem. 2014;115:421-6.
19. Sutherland ER, Goleva E, King TS, Lehman E, Stevens AD, Jackson LP, et al. Cluster analysis of obesity and asthma phenotypes. PLoS One. 2012;7:e36631.
20. Todd DC, Armstrong S, D'Silva L, Allen CJ, Hargreave FE, Parameswaran K. Effect of obesity on airway inflammation: a cross-sectional analysis of body mass index and sputum cell counts. Clin Exp Allergy. 2007;37:1049-54.
21. Schatz M, Hsu JW, Zeiger RS, Chen W, Dorenbaum A, Chipps BE, et al. Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2014;133:1549-56.
22. Gelfand EW, Kraft M. The importance and features of the distal airways in children and adults. J Allergy Clin Immunol. 2009;124:S84-7.
23. Gelb AF, Licuanan J, Shinar CM, Zamel N. Unsuspected loss of lung elastic recoil in chronic persistent asthma. Chest. 2002;121:715-21.
24. Dweik RA, Sorkness RL, Wenzel S, Hammel J, Curran-Everett D, Comhair SA, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med. 2010;181:1033-41.
25. Amelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman AH, Sterk PJ, et al. Severe adult-onset asthma: A distinct phenotype. J Allergy Clin Immunol. 2013;132:336-41.
26. Delgado-Corcoran C, Kissoon N, Murphy SP, Duckworth LJ. Exhaled nitric oxide reflects asthma severity and asthma control. Pediatr Crit Care Med. 2004;5:48-52.
27. Vlachos-Mayer H, Leigh R, Sharon RF, Hussack P, Hargreave FE. Success and safety of sputum induction in the clinical setting. Eur Respir J. 2000;16:997-1000.
28. Simpson JL, McElduff P, Gibson PG. Assessment and reproducibility of non-eosinophilic asthma using induced sputum. Respiration. 2010;79:147-51.
29. Yamamoto M, Tochino Y, Chibana K, Trudeau JB, Holguin F, Wenzel SE. Nitric oxide and related enzymes in asthma: relation to severity, enzyme function and inflammation. Clin Exp Allergy. 2012;42:760-8.
30. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax. 1998;53:91-5.
31. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003;22:470-7.
32. Kupczyk M, Wenzel S. U.S. and European severe asthma cohorts: what can they teach us about severe asthma? J Intern Med. 2012;272:121-32.
33. Kupczyk M, Haque S, Middelveld RJ, Dahlen B, Dahlen SE, Investigators B. Phenotypic predictors of response to oral glucocorticosteroids in severe asthma. Respir Med. 2013;107:1521-30.
34. Jarjour NN, Erzurum SC, Bleecker ER, Calhoun WJ, Castro M, Comhair SA, et al. Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med. 2012;185:356-62.
35. Moore WC, Hastie AT, Li X, Li H, Busse WW, Jarjour NN, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol. 2014;133:1557-63. e1555.
36. Modena BD, Tedrow JR, Milosevic J, Bleecker ER, Meyers DA, Wu W, et al. Gene Expression in Relation to Exhaled NO Identifies Novel Asthma Phenotypes with Unique Biomolecular Pathways. Am J Respir Crit Care Med. 2014;190(12):1363-72.
37. Wenzel SE, Busse WW, National Heart L, Blood Institute's Severe Asthma Research P. Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119:14-21. quiz 22-13.
38. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181:315-23.
39. Wu W, Bleecker E, Moore W, Busse WW, Castro M, Chung KF, et al. Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. J Allergy Clin Immunol. 2014;133:1280-8.
40. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax. 2011;66:910-7.
41. Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46:1308-21.